259 related articles for article (PubMed ID: 17509357)
21. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
22. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Thomas LN; Douglas RC; Lazier CB; Too CK; Rittmaster RS; Tindall DJ
Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
[TBL] [Abstract][Full Text] [Related]
23. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Andriole GL; Humphrey P; Ray P; Gleave ME; Trachtenberg J; Thomas LN; Lazier CB; Rittmaster RS
J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
[TBL] [Abstract][Full Text] [Related]
24. A model for the number of cores per prostate biopsy based on patient age and prostate gland volume.
Vashi AR; Wojno KJ; Gillespie B; Oesterling JE
J Urol; 1998 Mar; 159(3):920-4. PubMed ID: 9474183
[TBL] [Abstract][Full Text] [Related]
25. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer.
Kaplan SA; Lee RK; Chung DE; Te AE; Scherr DS; Tewari A; Vaughan ED
J Urol; 2012 Sep; 188(3):757-61. PubMed ID: 22818135
[TBL] [Abstract][Full Text] [Related]
26. Overview of pivotal studies for prostate cancer risk reduction, past and present.
Andriole GL
Urology; 2009 May; 73(5 Suppl):S36-43. PubMed ID: 19375625
[TBL] [Abstract][Full Text] [Related]
27. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 May; 177(5):1749-52. PubMed ID: 17437804
[TBL] [Abstract][Full Text] [Related]
28. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
Thomas LN; Douglas RC; Lazier CB; Gupta R; Norman RW; Murphy PR; Rittmaster RS; Too CK
J Urol; 2008 Jan; 179(1):147-51. PubMed ID: 17997435
[TBL] [Abstract][Full Text] [Related]
29. RE: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Pitts WR
J Urol; 2005 Apr; 173(4):1433-4; author reply 1434-5. PubMed ID: 15758829
[No Abstract] [Full Text] [Related]
30. High-grade prostate cancer and the prostate cancer prevention trial.
Logothetis CJ; Schellhammer PF
Cancer Prev Res (Phila); 2008 Aug; 1(3):151-2. PubMed ID: 19138948
[No Abstract] [Full Text] [Related]
31. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
32. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
33. Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.
Klein EA; Tangen CM; Goodman PJ; Lippman SM; Thompson IM
J Clin Oncol; 2005 Oct; 23(30):7460-6. PubMed ID: 16157937
[TBL] [Abstract][Full Text] [Related]
34. The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
Mellon JK
Eur J Cancer; 2005 Sep; 41(13):2016-22. PubMed ID: 16061372
[TBL] [Abstract][Full Text] [Related]
35. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
[TBL] [Abstract][Full Text] [Related]
36. Initial extended transrectal prostate biopsy--are more prostate cancers detected with 18 cores than with 12 cores?
Scattoni V; Roscigno M; Raber M; Dehò F; Maga T; Zanoni M; Riva M; Sangalli M; Nava L; Mazzoccoli B; Freschi M; Guazzoni G; Rigatti P; Montorsi F
J Urol; 2008 Apr; 179(4):1327-31; discussion 1331. PubMed ID: 18289580
[TBL] [Abstract][Full Text] [Related]
37. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
38. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
Marks LS; Andriole GL; Fitzpatrick JM; Schulman CC; Roehrborn CG
J Urol; 2006 Sep; 176(3):868-74. PubMed ID: 16890642
[TBL] [Abstract][Full Text] [Related]
39. Update on prostate cancer chemoprevention.
Lowe JF; Frazee LA
Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
[TBL] [Abstract][Full Text] [Related]
40. Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?
Grover S; Lowensteyn I; Hajek D; Trachtenberg J; Coupal L; Marchand S
J Urol; 2006 Mar; 175(3 Pt 1):934-8; discussion 938. PubMed ID: 16469585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
